US court issues opinion on vacating Risperdal exclusivity
This article was originally published in Scrip
Executive Summary
In late September, the US Court of Appeals for the District of Columbia reversed (without any memorandum) a lower court decision and thus vacated a ruling which had granted Teva Pharmaceutical Industries180 days of exclusivity for a generic version of Janssen's (Johnson & Johnson) Risperdal (risperidone) tablets (Scrip Online, September 22nd, 2008). Now, the appeals court has published its opinion, in a November 7th Circuit Court Opinion.